Vards

Cypress Associates LLC represented Finetre on the sale of Its VARDS business unit to MorningStar

NRG

Cypress Associates LLC  advised on the acquisition of and financing for certain power generation assets from Conectiv

ViryaNet

Cypress Associates LLC represented VirryaNet Ltd. in connection with the acquisition of eWise Systems Pty.

Equidyne

Cypress Associates LLC advised on the evaluation of strategic alternatives including a reverse merger of the Company

Sea Gate Travel Group

Cypress Associates LLC represented Sea Gate Travel Group in its sale to Hogg Robinson Plc, a portfolio company of Permira Advisors Limited

ITI Group

Cypress Associates LLC represented ITI Group on the sale of the Company’s stake in Grupa Onet to TVN

Imation Corp.

Imation Corp. (“Imation”) is a global data storage and information security company, whose products and solutions help store, manage and protect digital content.

Connected Data, Inc. (“Connected Data”) is a provider of enterprise-class, private cloud sync and share solutions to the SME market. Connected Data’s patented technology creates a mobile data infrastructure that delivers public cloud features without the expense or security compromises of cloud services.

A member of the Imation Board of Directors was both the CEO and shareholder in Connected Data; Imation’s Board formed a committee of independent directors to manage the Connected Data transaction.

Cypress acted as financial advisor to Imation in connection with the acquisition of Connected Data, and rendered fairness opinions.

Vector Oncology

Vector Oncology is a leader in the design and delivery of care based Health Economics and Outcomes Research (HEOR) and data analytics in oncology. Headquartered in Memphis, Vector Oncology utilizes its comprehensive Oncology Data Warehouse and proprietary Patient Care Monitor patient engagement and outcomes platform to design deliver high quality projects generating real world evidence and insight. Prior to the transaction, the Contract Research Organization(CRO) business unit was also wholly owned by the Company.

George Clinical is a leading Asia-Pacific based clinical research organization with global capabilities differentiated by scientific leadership and extensive site networks. Headquartered in Australia, George Clinical has a staff operating in 11 countries, and provides the full range of clinical trial services to pharmaceutical, medical device and biotech customers for all trial phases, registration and post-marketing trials. George Clinical’s parent organization, The George Institute for Global Health, is a leader in chronic disease research with a global network of experts with whom George Clinical engages.

The sale transaction provides Vector Oncology’s CRO with the ability to accelerate its international growth in oncology and to expand to other therapeutic areas. The acquisition enables George Clinical to expand its robust operational expertise and scientific leadership in vascular, renal and respiratory diseases, neurology and endocrinology throughout the United States.

Cypress Associates LLC acted as financial advisor to Vector Oncology in the sale of its CRO division to George Clinical.